SQSTM1 and hepatocellular carcinoma: The levels of p62 were not shown in six reports.12, 13, 14, 15, 16, 39 In three reports where p62 levels were shown, bortezomib treatment induced p62 degradation in myeloid leukemic cells,37 hepatocellular carcinoma,17 and lymphoma cells,38 suggesting that bortezomib activates autophagy.